REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
(Translation of Registrant’s name into English)
(Jurisdiction of incorporation or organization)
Chief Financial Officer
Innoviz Technologies Campus
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
The
|
|
|
The
|
☐ Large accelerated filer
|
☐ Accelerated filer
|
☒
|
|
☒
|
☐ International Financial Reporting Standards as issued by the International Accounting Standards Board
|
☐ Other
|
Page | |
1 | |
1 | |
1 | |
3 | |
3 | |
3 | |
3 | |
3 | |
A. Selected Financial Data |
3 |
B. Capitalization and Indebtedness |
3 |
C. Reasons for the Offer and Use of Proceeds |
3 |
D. Risk Factors |
3 |
30 | |
A. History and Development of the Company |
30 |
B. Business Overview |
31 |
C. Organizational Structure |
43 |
D. Property, Plant and Equipment |
43 |
44 | |
44 | |
A. Results of Operations |
47 |
B. Liquidity and Capital Resources |
50 |
C. Research and Development, Patents and Licenses, etc. |
52 |
D. Trend Information |
53 |
E. Critical Accounting Policies and Use of Estimates |
53 |
54 | |
A. Directors and Senior Management |
54 |
B. Compensation of Directors and Executive Officers |
57 |
C. Board Practices |
60 |
D. Employees |
68 |
E. Share Ownership |
68 |
F. Disclosure of a registrant’s action to recover erroneously awarded compensation
|
68 |
69 | |
A. Major Shareholders |
69 |
B. Related Party Transactions |
71 |
C. Interests of Experts and Counsel |
72 |
72 | |
A. Consolidated Statements and Other Financial Information |
72 |
B. Significant Changes |
72 |
72 | |
A. Offer and Listing Details |
72 |
B. Plan of Distribution |
72 |
C. Markets |
72 |
D. Selling Shareholders |
72 |
E. Dilution |
72 |
F. Expenses of the Issue |
72 |
73 | |
A. Share Capital |
73 |
B. Memorandum and Articles of Association |
73 |
C. Material Contracts |
74 |
D. Exchange Controls |
75 |
E. Taxation |
75 |
F. Dividends and Paying Agents |
85 |
G. Statement by Experts |
85 |
H. Documents on Display |
85 |
I. Subsidiary Information |
86 |
J. Annual Report to Security
Holders |
86 |
86 | |
86 | |
86 | |
86 | |
86 | |
87 | |
87 | |
87 | |
87 | |
88 | |
88 | |
88 | |
89 | |
89 | |
89 | |
89 | |
89 | |
90 | |
90 | |
90 | |
91 | |
93 | |
F-1 |
• |
our limited operating history and evolving business model makes evaluating our business and future prospects difficult and may increase
the risk of your investment; |
• |
continued pricing pressures, automotive original equipment manufacturers (“OEM”) cost reduction initiatives and the ability
of automotive OEMs to re-source or cancel vehicle or technology programs may result in lower than anticipated margins, or in
incremental losses, which may adversely affect our business; |
• |
we are creating innovative technologies by designing and developing unique components. The high price of, or low yield in these components,
may affect our ability to sell at competitive prices or may lead to losses; |
• |
there are significant risks to providing our products as a direct supplier
to customers, including additional operating costs, increased liabilities, and additional indemnification responsibilities, in each case,
that we did not previously face when acting as a Tier-2 supplier; |
• |
we expect to invest substantially in research and development for the purpose of developing and commercializing new products. These
investments could significantly reduce our profitability or increase our losses and may not generate revenue for us; |
• |
we will likely need to raise additional funds in the
future in order to execute our business plan and these funds may not be available to us when we need them. If we cannot raise additional
funds when we need them, our business, prospects, financial condition and operating results could be negatively affected; |
• |
we may experience significant delays in the design, production and launch of our LiDAR products, which could harm our business, prospects,
financial condition and operating results; |
• |
we are substantially dependent on a limited number of customers. The automotive industry is comprised of a relatively small number
of players, which makes each design win material for us, and our business could be materially and adversely affected if any of our customers
terminate our programs following such wins; |
• |
designing and manufacturing LiDARs
and LiDAR components on a mass-production scale requires meeting stringent quality requirements and we may face significant challenges
and complexities in this process; |
• |
the period of time from a design
win to implementation is long and we are subject to the risk of cancellations or postponement of contracts or failure to successfully
meet customers’ requirements for start of production (“SOP”); |
• |
certain of our strategic, development and supply arrangements could be terminated or may not materialize into long-term contract
partnership arrangements; |
• |
we target many customers that are large companies with substantial negotiating power, exacting product standards and potentially
competitive internal solutions. If we are unable to sell our products to these customers, our prospects and results of operations will
be adversely affected; |
• |
we continue to implement strategic initiatives designed to grow our business. These initiatives may prove more costly than we currently
anticipate and we may not succeed in increasing our revenues by an amount sufficient to offset the costs of these initiatives and to achieve
and maintain profitability; |
• |
the first vehicles deploying our
LiDAR technology and software are expected to become commercially available to end users in 2024. If any vehicles deploying our LiDAR
technology and software are involved in traffic accidents or collisions actually or allegedly resulting from undetected defects, errors,
or bugs in our products, or if our products actually or allegedly fail to perform as expected, we may be exposed to product liability,
warranty and other claims, in addition to a decline in the market adoption of our products, damage to our reputation with current or prospective
customers, or increased regulatory scrutiny of our solutions which would adversely affect our operating costs, business and prospects;
|
• |
we operate in a highly competitive market against a large number of both established competitors
and new market entrants, and some market participants have substantially greater resources than ours; and |
• |
the other matters described in the section entitled Item 3.D. “Key Information—Risk
Factors” beginning on page 3. |
Item
1. |
Identity of Directors,
Senior Management and Advisers |
Item 2. |
Offer Statistics and Expected Timetable |
Item 3. |
Key Information |
• |
Our limited operating history and evolving business model makes evaluating our business and future prospects difficult and may increase
the risk of your investment. |
• |
Continued pricing pressures, automotive OEM cost reduction initiatives and the ability of automotive OEMs to re-source or cancel
vehicle or technology programs may result in lower than anticipated margins, or in incremental losses, which may adversely affect our
business. |
• |
We are creating innovative technologies by designing
and developing unique components. The high price of, or low yield in these components, may affect our ability to sell at competitive prices
or may lead to losses. |
• |
There are significant risks to providing our products
as a direct supplier to customers, including additional operating costs, increased liabilities, and additional indemnification responsibilities,
in each case, that we did not previously face when acting as a Tier-2 supplier. |
• |
We expect to invest substantially in research and development for the purpose of developing and commercializing new products. These
investments could significantly reduce our profitability or increase our losses and may not generate revenue for us. |
• |
We will likely need to raise additional
funds in the future in order to execute our business plan and these funds may not be available to us when we need them. If we cannot raise
additional funds when we need them, our business, prospects, financial condition and operating results could be negatively affected.
|
• |
We may experience significant delays in the design, production and launch of our LiDAR products, which could harm our business, prospects,
financial condition and operating results. |
• |
We are substantially dependent on a limited number of customers. The automotive industry is comprised of a relatively small number
of players, which makes each design win material for us, and our business could be materially and adversely affected if any of our customers
terminate our programs following such wins. |
• |
Designing and manufacturing LiDARs
and LiDAR components on a mass-production scale requires meeting stringent quality requirements and we may face significant challenges
and complexities in this process. |
• |
The period of time from a design
win to implementation is long and we are subject to the risk of cancellations or postponement of contracts or failure to successfully
meet customers’ requirements for SOP. |
• |
If market adoption of LiDAR for autonomous vehicles does not continue to develop, or develops more slowly than we expect, our business
will be adversely affected. |
• |
Certain of our strategic, development
and supply arrangements could be terminated or may not materialize into long-term contract partnership arrangements. |
• |
We target many customers that are large companies with substantial negotiating power, exacting product standards and potentially
competitive internal solutions. If we are unable to sell our products to these customers, our prospects and results of operations will
be adversely affected. |
• |
We continue to implement strategic initiatives designed to grow our business. These initiatives may prove more costly than we currently
anticipate, and we may not succeed in increasing our revenues by an amount sufficient to offset the costs of these initiatives and to
achieve and maintain profitability. |
• |
The markets in which we compete
are characterized by rapid technological change, which requires us to continue to develop new products and product innovations and could
adversely affect market adoption of our products. |
• |
Certain of our strategic, development and supply arrangements could be terminated or may not materialize into long-term contract
partnership arrangements. |
• |
Adoption of LiDAR for other emerging markets may not
occur or may occur much more slowly than we anticipate, which would adversely affect our business and prospects. |
• |
Adverse conditions in the automotive industry or the global economy more generally could have adverse effects on our results of operations.
|
• |
We may experience difficulties in expanding our operations. |
• |
As part of growing our business, we may in the future make acquisitions. If we fail to successfully select, execute or integrate
our acquisitions, then our business, results of operations and financial condition could be materially and adversely affected and the
price of our ordinary shares and warrants could decline. |
• |
The first vehicles deploying our LiDAR technology
and software are expected to become commercially available to end users in 2024. If any vehicles deploying our LiDAR technology and software
are involved in traffic accidents or collisions actually or allegedly resulting from undetected defects, errors, or bugs in our products,
or if our products actually or allegedly fail to perform as expected, we may be exposed to product liability, warranty and other claims,
in addition to a decline in the market adoption of our products, damage to our reputation with current or prospective customers, or increased
regulatory scrutiny of our solutions which would adversely affect our operating costs, business and prospects.
|
• |
We operate in a highly competitive
market against a large number of both established competitors and new market entrants, and some market participants have substantially
greater resources than ours. |
• |
We rely on third-party suppliers and are susceptible to supply shortages, long lead times for components and supply changes, any
of which could disrupt our supply chain and could delay deliveries of our products to customers. |
• |
Our sales and operations in international markets expose us to operational, financial and regulatory risks. |
• |
We may not be able to adequately protect or enforce our intellectual property rights or prevent unauthorized parties from copying
or reverse engineering our solutions. Our efforts to protect and enforce our intellectual property rights and prevent third parties from
violating our rights may be costly. |
• |
Our business may be adversely affected by changes in automotive safety regulations or concerns that drive further regulation of the
automobile safety market. |
• |
Failures, or perceived failures, to comply with privacy, data protection, and information security requirements in the variety of
jurisdictions in which we operate, may adversely impact our business, and such legal requirements are evolving, uncertain and may require
improvements in, or changes to, our policies and operations. |
• |
As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial
reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company
and, as a result, the value of our ordinary shares. |
• |
The market price and trading volume of our ordinary shares and warrants may be volatile and could decline significantly. |
• |
We expect our results of operations to fluctuate
on a quarterly and annual basis, which could cause the price of our ordinary shares and warrants to fluctuate or decline. |
• |
We may lose our “foreign private issuer” status in the future, which could result in significant additional costs and
expenses. |
• |
As we are a “foreign private issuer” and follow certain home country corporate governance practices, our shareholders
may not have the same protections afforded to shareholders of companies that are subject to all corporate governance requirements of the
Nasdaq Stock Market LLC (“Nasdaq”). |
• |
The war in Israel and other conditions in Israel could materially and
adversely affect our business. |
• |
The tax benefits that are available to us require that we continue to meet various conditions and may be terminated or reduced in
the future, which could increase our costs and taxes. |
• |
The rights and responsibilities of our shareholders are governed by Israeli law, which may differ in some respects from the rights
and responsibilities of shareholders of U.S. corporations. |
• |
investing in research and development; |
• |
attracting and retaining talent to develop, support and promote our business across different functions and geographies, further
enhancing our manufacturing processes and partnerships; and |
• |
investing in legal, accounting and other administrative functions necessary to support our operations as a public company.
|
• |
changes in tax laws or the regulatory environment; |
• |
changes in accounting and tax standards or practices; |
• |
changes in the composition of operating income by tax jurisdiction; and |
• |
our operating results before taxes. |
• |
exchange rate fluctuations; |
• |
political and economic instability, international terrorism and anti-Israeli sentiment, such as the war and hostilities between Israel
and Hamas and Israel and Hezbollah; |
• |
global or regional health crises; |
• |
potential for violations of anti-corruption laws and regulations, such as those related to bribery and fraud; |
• |
preference for locally branded products, and laws and business practices favoring local competition; |
• |
potential complexities of operating in China with increased data collection regulations, and government-mandates which are subject
to change per unprecedented regulation; |
• |
increased difficulty in managing inventory; |
• |
delayed revenue recognition; |
• |
less effective protection of intellectual property; |
• |
stringent regulation of the autonomous or other systems or products using our products and stringent consumer protection and product
compliance regulations, including but not limited to General Data Protection Regulation in the European Union (the “EU”),
European competition law, the Restriction of Hazardous Substances directive, the Waste Electrical and Electronic Equipment directive and
the European Ecodesign directive that are costly to comply with, and may vary from country to country; |
• |
difficulties and costs of staffing and managing foreign operations; |
• |
import and export laws and the impact of tariffs; and |
• |
changes in local tax and customs duty laws, or changes in the enforcement, application or interpretation of such laws. |
• |
a limited availability of market quotations for our ordinary shares and warrants; |
• |
a reduced level of trading activity in the secondary trading market for our ordinary shares and warrants; |
• |
a limited amount of news and analyst coverage for us; |
• |
a decreased ability to issue additional securities or obtain additional financing in the future; and |
• |
our securities would not be “covered securities” under the National Securities Markets Improvement Act of 1996, which
is a federal statute that prevents or pre-empts the states from regulating the sale of certain securities, including securities
listed on Nasdaq, in which case our securities would be subject to regulation in each state where we offer and sells securities.
|
• |
the realization of any of the risk factors presented in this Annual Report; |
• |
actual or anticipated differences in our estimates, or in the estimates of analysts, for our revenues, Adjusted EBITDA, results of
operations, level of indebtedness, liquidity or financial condition; |
• |
availability of capital to fund our contracts and our growth; |
• |
additions and departures of key personnel; |
• |
failure to comply with the requirements of Nasdaq; |
• |
failure to comply with the Sarbanes-Oxley Act or other laws or regulations; |
• |
future issuances, sales, resales or repurchases or anticipated issuances, sales, resales or repurchases, of our securities including
due to the exercise of warrants; |
• |
publication of research reports about us; |
• |
the performance and market valuations of other similar companies; |
• |
failure of securities analysts to initiate or maintain coverage of our company, changes in financial estimates by any securities
analysts who follow us or our failure to meet these estimates or the expectations of investors; |
• |
the effects of the war and hostilities between Israel and Hamas and Israel and Hezbollah; |
• |
the effects of our operational realignment; |
• |
new laws, regulations, subsidies, or credits or new interpretations of existing laws applicable to us; |
• |
commencement of, or involvement in, litigation involving us; |
• |
broad disruptions in the financial markets, including sudden disruptions in the credit markets; |
• |
speculation in the press or investment community; |
• |
actual, potential or perceived control, accounting or reporting problems; |
• |
changes in accounting principles, policies and guidelines; and |
• |
other events or factors, including those resulting from infectious diseases, health epidemics and pandemics, natural disasters, war,
acts of terrorism or responses to these events. |
• |
the timing and magnitude of orders and shipments of our products in any quarter; |
• |
the timing and magnitude of any NREs; |
• |
pricing changes we may adopt to drive market adoption or in response to competitive pressure; |
• |
our ability to attract and retain talent to develop, support, and promote our business across different functions and geographies;
|
• |
our ability to retain our existing customers and attract new customers; |
• |
our ability to develop, introduce, manufacture
and ship in a timely manner products that meet customer requirements; |
• |
disruptions in our sales channels or termination of our relationship with important channel partners; |
• |
delays in customers’ purchasing cycles or deferments of customers’ purchases in anticipation of new products or updates
from us or our competitors; |
• |
fluctuations in demand pressures for our products; |
• |
the mix of products sold in any quarter; |
• |
the timing and rate of broader market adoption of autonomous systems utilizing our solutions across the automotive and other market
sectors; |
• |
market acceptance of LiDAR and further technological advancements by our competitors and other market participants; |
• |
the ability of our customers to commercialize systems that incorporate our products; |
• |
any change in the competitive dynamics of our markets, including consolidation of competitors, regulatory developments and new market
entrants; |
• |
our ability to effectively manage our inventory; |
• |
changes in the source, cost, availability of and regulations pertaining to materials we use; |
• |
adverse litigation, judgments, settlements or other litigation-related costs, or claims that may give rise to such costs; and
|
• |
general economic, industry and market conditions, including trade disputes. |
Item 4. |
Information on the Company. |
• |
unique scanning mechanisms for improved scanner size and better collection of received light; |
• |
silicon detectors for improved optical–electrical conversion of the received signal; and |
• |
the signal processing application-specific integrated circuit (“ASIC”) (the chip that processes the signal coming from
the detectors and controls the system functions) in order to improve the optical link budget of the system, while also getting the best
possible detection capabilities for a given optical link budget. We have achieved industry leading point-cloud quality by developing and
using custom signal processing algorithms implemented in a proprietary ASIC. |
Innoviz One |
Innoviz Two |
|
|
* |
Product size may differ according to specifications |
• |
InnovizOne —a solid-state LiDAR sensor specifically designed for automakers and robotaxis, shuttles, trucks and delivery companies
requiring an automotive-grade, mass-producible solution to achieve autonomy. The automotive-grade sensor is purpose-built to be rugged,
affordable, reliable, low-power consuming, lightweight, high-performing and seamlessly integrable into Level 3 through
5 autonomous vehicles to ensure the safety of passengers and pedestrians alike. InnovizOne was classified as a laser class 1 product under
European standard IEC 60825-1 Rev 3 Class 1 on September 24, 2019. |
• |
InnovizTwo —announced in the fourth quarter of 2020, InnovizTwo is a next generation high-performance automotive-grade LiDAR
sensor that is currently in development, and engineering samples have been produced for demonstrations and evaluations. InnovizTwo will
offer a fully featured solution for all levels of autonomous driving. Featuring a major cost reduction compared to InnovizOne, InnovizTwo
also includes improved lasers and detectors that increase range performance at a lower system cost, which is expected to provide a significant
performance improvement over InnovizOne. InnovizTwo will also offer the option to integrate the Perception Application (see below) in
the LiDAR sensor itself. |
• |
Perception Application —software application that turns raw point cloud data from Innoviz LiDAR products into perception outputs.
The outputs can serve as a standalone, functionally safe perception software, or can be integrated into the vehicle’s existing perception
stack at different levels to support various sensor fusion architectures. In addition, our software leverages the rich data derived from
our LiDAR products, coupled with proprietary state-of-the-art artificial intelligence-based algorithms, to provide superior
scene perception and deliver an automotive-grade ASIL B(D) solution. |
Item 4A. |
Unresolved Staff Comments |
Item 5. |
Operating and Financial Review and Prospects |
• |
personnel-related expenses, including salaries, benefits, and stock-based compensation expense for personnel in research and engineering
functions; |
• |
expenses related to materials, software licenses, depreciation, supplies and third-party services; |
• |
prototype expenses; and |
• |
an allocated portion of facility and IT costs. |
• |
personnel-related expenses, including salaries, benefits, and stock-based compensation expense for personnel in sales and marketing;
|
• |
sales and marketing activities, including the cost of sales commissions, marketing programs, trade shows, consulting services, promotional
materials and demonstration equipment, among other costs; and |
• |
an allocated portion of facility and IT costs. |
• |
personnel-related expenses, including salaries, benefits, and stock-based compensation expense for personnel in corporate, executive,
finance and other administrative functions; |
• |
general and administration activities, including expenses relating to outside professional services, including legal, investors relations
and audit and accounting services; and |
• |
the relevant portion of expenses for facilities, depreciation and IT costs that was not allocated to other operating expenses.
|
Year ended December 31, |
||||||||
2023 |
2022 |
|||||||
(In thousands, except share and per share data) |
||||||||
Revenues
|
$ |
20,876 |
$ |
6,026 |
||||
Cost of revenues
|
(32,490 |
) |
(14,790 |
) | ||||
Gross loss
|
(11,614 |
) |
(8,764 |
) | ||||
Operating expenses: |
||||||||
Research and development
|
92,676 |
95,107 |
||||||
Sales and marketing
|
8,777 |
10,300 |
||||||
General and administrative
|
19,535 |
19,178 |
||||||
Total operating expenses
|
120,988 |
124,585 |
||||||
Operating loss
|
(132,602 |
) |
(133,349 |
) | ||||
Financial income, net
|
9,790 |
6,802 |
||||||
Loss before taxes on income
|
(122,812 |
) |
(126,547 |
) | ||||
Taxes on income
|
(642 |
) |
(325 |
) | ||||
Net loss
|
$ |
(123,454 |
) |
$ |
(126,872 |
) | ||
Basic and diluted net loss per ordinary share
|
$ |
(0.84 |
) |
$ |
(0.94 |
) | ||
Weighted average number of ordinary shares used in computing
basic and diluted net loss per ordinary share |
147,480,521 |
135,224,312 |
Year ended December 31, |
Change |
Change |
||||||||||||||
2023 |
2022 |
$ |
% |
|||||||||||||
(In thousands) |
(In thousands) |
(In thousands) |
||||||||||||||
Revenues |
$ |
20,876 |
$ |
6,026 |
$ |
14,850 |
246 |
% |
Year ended December 31, |
Change |
Change |
||||||||||||||
2023 |
2022 |
$ |
% |
|||||||||||||
(In thousands except
percentages) |
(In thousands) |
|||||||||||||||
Cost of revenues
|
$ |
32,490 |
$ |
14,790 |
$ |
17,700 |
120 |
% | ||||||||
Gross margin |
(56 |
)% |
(145 |
)% |
Year ended December 31, |
Change |
Change |
||||||||||||||
2023 |
2022 |
$ |
% |
|||||||||||||
(In thousands) |
(In thousands) |
(In thousands) |
||||||||||||||
Research and development
|
$ |
92,676 |
$ |
95,107 |
$ |
(2,431 |
) |
(3 |
)% | |||||||
Sales and marketing
|
8,777 |
10,300 |
(1,523 |
) |
(15 |
)% | ||||||||||
General and administrative
|
19,535 |
19,178 |
357 |
2 |
% | |||||||||||
Total operating expenses
|
$ |
120,988 |
$ |
124,585 |
$ |
(3,597 |
) |
(3 |
)% |
Year ended December 31 |
Change |
Change |
||||||||||||||
2023 |
2022 |
$ |
% |
|||||||||||||
(In thousands) |
(In thousands) |
(In thousands) |
||||||||||||||
Financial income, net
|
$ |
9,790 |
$ |
6,802 |
$ |
2,988 |
44 |
% |
Year ended December 31, |
||||||||
2023 |
2022 |
|||||||
(In thousands) |
(In thousands) |
|||||||
Net cash used in operating activities |
$ |
(93,053 |
) |
$ |
(93,411 |
) | ||
Net cash provided by investing activities |
1,064 |
125,354 |
||||||
Net cash provided by financing activities |
61,856 |
609 |
||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
515 |
(1,139 |
) | |||||
Net increase (decrease) in cash, cash equivalents and restricted cash |
$ |
(29,618 |
) |
$ |
31,413 |
• |
expand production capabilities to produce our LiDAR solutions, and accordingly incur costs associated with outsourcing the production
of our LiDAR solutions; |
• |
expand our design, development, installation and servicing capabilities; |
• |
continue to invest in research and development; |
• |
increase our test and validation activities as part of our Tier 1 responsibilities; |
• |
produce an inventory of our LiDAR solutions; and |
• |
continue to invest in sales and marketing activities and develop our
distribution infrastructure. |
• |
Raw materials and work in process - based on weighted average cost. |
• |
Finished goods – mainly based on weighted average standard cost method. |
Item 6. |
Directors, Senior Management and Employees |
Name |
Age |
Position(s) | ||
Omer Keilaf |
44 |
Chief Executive Officer, Co-Founder and Director | ||
Eldar Cegla |
54 |
Chief Financial Officer | ||
Avishay Moscovici |
56 |
Chief Research & Development Officer | ||
Elad Hofstetter |
42 |
Chief Business Officer | ||
Udy Gal-On |
55 |
Chief Operating Officer | ||
Amichai Steimberg |
61 |
Chairperson of the Board of Directors
| ||
Aharon Aharon |
69 |
Director | ||
Dan Falk |
79 |
Director | ||
Stefan Jacoby |
66 |
Director | ||
Ronit Maor |
53 |
Director | ||
James Sheridan |
56 |
Director | ||
Orit Stav |
53 |
Director | ||
Alexander von Witzleben |
60 |
Director | ||
Name and Principal Position(1)
|
Salary and benefits(2)
|
Bonus |
Equity-Based Compensation(3)
|
Total |
||||||||||||
Omer Keilaf (Chief Executive
Officer) |
$ |
$432,704 |
$ |
0 |
$ |
$2,962,154 |
$ |
$3,394,858 |
||||||||
Oren Buskila (former Chief
Research & Development Officer) |
$ |
$350,376 |
$ |
0 |
$ |
$1,759,057 |
$ |
$2,109,432 |
||||||||
Udy Gal-On (Chief Operating
Officer) |
$ |
$249,684 |
$ |
0 |
$ |
$371,526 |
$ |
$621,209 |
||||||||
Eldar Cegla (Chief Financial
Officer) |
$ |
$295,554 |
$ |
0 |
$ |
$272,703 |
$ |
$568,256 |
||||||||
Avishay Moscovici (Chief Research
& Development Officer) |
$ |
$231,021 |
$ |
0 |
$ |
$213,436 |
$ |
$444,457 |
(1) |
All Covered Executives were employed on a full time (100%) basis during 2023. Mr. Buskila resigned from his position as Chief Research
& Development Officer on February 28, 2024. |
(2) |
Includes the Covered Executive’s gross salary and benefits and perquisites, including those mandated by applicable law. Such
benefits and perquisites may include, to the extent applicable to the Covered Executives, payments, contributions and/or allocations for
savings funds (e.g., Managers’ Life Insurance Policy), education funds (referred to in Hebrew as “keren hishtalmut”),
pension, severance, vacation, car or car allowance, medical insurances and benefits, risk insurance (e.g., life, disability, accident),
telephone, convalescence pay, payments for social security, tax gross-up payments and other benefits and perquisites consistent with the
Company’s policies. |
(3) |
Represents the equity-based compensation expenses recorded in the Company’s consolidated financial statements for the year
ended December 31, 2023, based on the equity fair value on the grant date, calculated in accordance with accounting guidance for equity-based
compensation. For a discussion on the assumptions used in reaching this valuation, see Note 12 to our consolidated financial statements
included in this Annual Report. |
• |
at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest
in such matter, present and voting at such meeting, are voted in favor of the compensation package, excluding abstentions; or |
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such
matter voting against the compensation package does not exceed 2% of the aggregate voting rights in the company. |
• |
the Class I directors are Aharon Aharon, Stefan Jacoby and Orit Stav and their terms expire at our annual general meeting to
be held in 2024; |
• |
the Class II directors are Dan Falk and Ronit Maor and their terms expire at our annual general meeting to be held in 2025;
and |
• |
the Class III directors are Amichai Steimberg, Omer Keilaf and Alexander von Witzleben and their terms expire at our annual
general meeting to be held in 2026. |
• |
the director is, or at any time during the past three years was, an employee of our company; |
• |
the director or a family member of the director accepted any compensation from our company in excess of $120,000 during any period
of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among
other things, compensation for board or board committee service); |
• |
a family member of the director is, or at any time during the past three years was, an executive officer of our company; |
• |
the director or a family member of the director is a partner in, controlling shareholder of, or an executive officer of an entity
to which our company made, or from which our company received, payments in the current or any of the past three fiscal years that exceed
5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
|
• |
the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past
three years, any of the executive officers of our company served on the compensation committee of such other entity; or |
• |
the director or a family member of the director is a current partner of our outside auditor, or at any time during the past three
years was a partner or employee of our outside auditor, and who worked on our audit. |
• |
at least a majority of the shares of non-controlling shareholders or shareholders that do not have a personal interest
in the approval voted at the meeting are voted in favor (disregarding abstentions); or |
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such
appointment voting against such appointment does not exceed 2% of the aggregate voting rights in the Company. |
• |
recommending to the board of directors the retention and termination of the internal auditor, and the internal auditor’s engagement
fees and terms, in accordance with the Companies Law as well as approving the yearly or periodic work plan proposed by the internal auditor;
|
• |
reviewing with our general counsel and/or external counsel, as deemed necessary, legal and regulatory matters that could have a material
impact on the financial statements; |
• |
identifying irregularities in our business administration, including by consulting with the internal auditor or with the independent
auditor, and suggesting corrective measures to the board of directors; |
• |
reviewing policies and procedures with respect to transactions (other than transactions related to the compensation or terms of services)
between the Company and officers and directors, or affiliates of officers or directors, or transactions that are not in the ordinary course
of the Company’s business and deciding whether to approve such acts and transactions if so required under the Companies Law; and
|
• |
establishing procedures for the handling of employees’ complaints as to the management of our business and the protection to
be provided to such employees. |
• |
recommending to the board of directors with respect to the approval of the compensation policy for “office holders” (a
term used under the Companies Law, which means, in effect, directors and executive officers) and, once every three years, regarding any
extensions to a compensation policy that has been in effect for a period of more than three years; |
• |
reviewing the implementation of the compensation policy and periodically recommending to the board of directors with respect to any
amendments or updates of the compensation plan; |
• |
resolving whether or not to approve arrangements with respect to the terms of office and employment of office holders; and
|
• |
exempting, under certain circumstances, from the requirement of approval by the general meeting of shareholders, transactions with
the chief executive officer of our company. |
• |
such majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and do not have
a personal interest in such compensation policy and who are present and voting (excluding abstentions); or |
• |
the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the
compensation policy and who vote against the policy, does not exceed 2% of the company’s aggregate voting rights. |
• |
the education, skills, experience, expertise and accomplishments of the relevant office holder; |
• |
the office holder’s position, responsibilities and prior compensation agreements with him or her; |
• |
the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the
company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost,
the average and median salary of the employees of the company, as well as the impact of such disparities on the work relationships in
the company; |
• |
if the terms of employment include variable components—the possibility of reducing variable components at the discretion of
the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and
|
• |
if the terms of employment include severance compensation—the term of employment or office of the office holder, the terms
of his or her compensation during such period, the company’s performance during such period, his or her individual contribution
to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the
company. |
• |
with regard to variable components of compensation: |
• |
with the exception of office holders who report directly to the chief executive officer, provisions determining the variable components
on the basis of long-term performance and on measurable criteria; however, the company may determine that an immaterial part of the variable
components of the compensation package of an office holder shall be awarded based on non-measurable criteria, if such amount
is not higher than three monthly salaries per annum, while taking into account such office holder’s contribution to the company;
and |
• |
the ratio between variable and fixed components, as well as the limit on the values of variable components at the time of their grant.
|
• |
a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation
policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on information later to be discovered
to be wrong, and such information was restated in the company’s financial statements; |
• |
the minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable,
while taking into consideration long-term incentives; and |
• |
a limit on retirement grants. |
• |
identify, review and evaluate candidates to serve as members of our board of directors, recommend to our board of directors nominees
for election as directors of the Company, and review and evaluate incumbent members of the board of directors; |
• |
make recommendations to our board of directors regarding corporate governance guidelines and matters; |
• |
oversee all aspects of the Company’s corporate governance functions and ethical conduct; and |
• |
oversee the Company’s programs and strategies related to environmental, social and governance matters. |
• |
a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s
award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance,
then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s
activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors
as reasonable under the circumstances, and such undertaking shall detail the abovementioned events and amount or criteria; |
• |
reasonable litigation expenses, including legal fees, incurred by the office holder (1) as a result of an investigation or proceeding
instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that
(i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial
liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation
or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
intent; and (2) in connection with a monetary sanction; |
• |
reasonable litigation expenses, including legal fees, incurred by the office holder or imposed by a court in proceedings instituted
against him or her by the company, on its behalf or by a third-party or in connection with criminal proceedings in which the
office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent; and |
• |
expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative
proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder
by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law, 1968 (the “Israeli Securities Law”).
|
• |
a breach of the duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis
to believe that the act would not prejudice the company; |
• |
a breach of the duty of care to the company or to a third-party, including a breach arising out of the negligent conduct
of the office holder; |
• |
a financial liability imposed on the office holder in favor of a third-party; |
• |
a financial liability imposed on the office holder in favor of a third-party harmed by a breach in an administrative proceeding;
and |
• |
expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative
proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law. |
• |
a breach of the duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not prejudice the company; |
• |
a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the
office holder; |
• |
an act or omission committed with intent to derive illegal personal benefit; or |
• |
a fine, monetary sanction or forfeit levied against the office holder. |
Item 7. |
Major Shareholders and Related Party Transactions |
• |
each person or entity known by us to own beneficially more than 5% of our outstanding shares; |
• |
each of our directors and executive officers individually; and |
• |
all of our executive officers and directors as a group. |
Name of Beneficial Owner |
Number |
% |
||||||
Five
Percent or More Holders |
||||||||
Antara Capital LP (1)
|
18,627,642 |
11.2 |
% | |||||
Citigroup Global Markets Inc. (2)
|
11,635,265 |
7.0 |
% | |||||
FIFTHDELTA LTD (3)
|
8,728,403 |
5.3 |
% | |||||
Directors
and Executive Officers |
||||||||
Omer Keilaf (4)
|
4,578,590 |
2.7 |
% | |||||
Eldar Cegla (5)
|
483,586 |
* |
||||||
Elad Hofstetter (6)
|
108,903 |
* |
||||||
Avishay Moscovici (7)
|
271,375 |
* |
||||||
Udy Gal-On (8)
|
164,441 |
* |
||||||
Amichai Steimberg (9)
|
211,255 |
* |
||||||
Aharon Aharon (10)
|
63,503 |
* |
||||||
Dan Falk (10)
|
63,503 |
* |
||||||
Ronit Maor (10)
|
63,503 |
* |
||||||
Orit Stav (10)
|
63,503 |
* |
||||||
James Sheridan (11)
|
3,186,172 |
1.9 |
% | |||||
Alexander von Witzleben (12)
|
15,274 |
* |
||||||
Stefan Jacoby (13)
|
10,500 |
* |
||||||
All executive officers and directors
as a group (13 persons) |
9,284,108 |
5.4 |
% |
* |
less than 1% |
(1) |
Based on information reported on Schedule 13G/A filed with
the SEC on February 14, 2024 and other information available to the Company, Antara Capital Master Fund LP (“Antara Master Fund”)
directly holds 865,900 ordinary shares and options to purchase 6,003,200 ordinary shares. Certain managed accounts for which Antara Capital
LP (“Antara Capital”) serves as investment manager (the “Managed Accounts”) directly hold 3,527,850 ordinary shares.
In addition, Antara Master Fund directly holds warrants to purchase 8,230,692 ordinary shares at an exercise price of $11.50 per ordinary
share, which are presently exercisable, and will expire five years after April 5, 2021 or earlier upon redemption or liquidation. The
foregoing amounts do not include 312,296 ordinary shares to be issued to Antara Master Fund upon the satisfaction of certain earn-out
conditions. Antara Capital is the investment manager of the Antara Master Fund and the Managed Accounts. Antara Capital GP LLC (“Antara
GP”) is the general partner of Antara Capital. Himanshu Gulati (“Mr. Gulati”) is the sole member of Antara GP. Antara
Capital, Antara GP and Mr. Gulati may be deemed to beneficially own the securities of the company held directly by Antara Master Fund
and the Managed Accounts. The business address of the foregoing persons is 55 Hudson Yards, 47th Floor,
Suite C, New York, NY 10001. |
(2) |
Based on information reported on Schedule 13G filed with the SEC on February
12, 2024, each of Citigroup Global Markets Inc. (“CGM”), Citigroup Financial Products Inc. (“CFP”), Citigroup
Global Markets Holdings Inc.(“CGM Holdings”) and Citigroup Inc. (“Citigroup”), has the shared power to vote or
direct to vote 11,635,265 ordinary shares and the shared power to dispose or to direct the disposition of 11,635,265 ordinary shares.
The business address of each of CGM, CFP, CGM Holdings and Citigroup is, 388 Greenwich Street, New York, NY 10013. |
(3) |
Based on information reported on Schedule 13G/A filed with the SEC on
February 12, 2024, FIFTHDELTA Master Fund Limited (the “Master Fund”), an exempted company incorporated in the Cayman Islands
with limited liability, directly holds 8,728,403 ordinary shares. FIFTHDELTA LTD (the “Manager”), a private limited company
organized under the laws of England and Wales, serves as investment manager to the Master Fund and has discretionary and voting power
over the ordinary shares held by the Master Fund. Accordingly, the Manager may be deemed to be the beneficial owner of 8,728,403 ordinary
shares which are held by the Master Fund. The Manager disclaims beneficial ownership of the Shares of the Issuer held by the Master Fund,
except to the extent of any pecuniary interest therefrom. The business address of the Manager is 15 Sackville Street, 1st Floor, London
W1S 3DJ, United Kingdom and the business address for the Master Fund is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town,
Grand Cayman, KY1-9008, Cayman Islands. |
(4) |
Consists of 2,772,753 ordinary shares and 1,805,837 ordinary shares issuable upon vesting of RSUs or exercise of options that are
exercisable as of or within 60 days of March 1, 2024. |
(5) |
Consists of 173,863 ordinary shares and 309,723 ordinary shares issuable upon vesting of RSUs or exercise of options that are exercisable
as of or within 60 days of March 1, 2024. |
(6) |
Consists of 18,242 ordinary shares and 90,661 ordinary shares issuable upon vesting of RSUs or exercise of options that are exercisable
as of or within 60 days of March 1, 2024. |
(7) |
Consists of 74,029 ordinary shares and 197,346 ordinary shares issuable upon vesting of RSUs or exercise of options that are exercisable
as of or within 60 days of March 1, 2024. |
(8) |
Consists of 44,304 ordinary shares and 120,137 ordinary shares issuable upon vesting of RSUs or exercise of options that are exercisable
within 60 days of March 1, 2024. |
(9) |
Consists of 83,354 ordinary shares and 127,901 ordinary shares issuable upon vesting of RSUs or exercise of options that are exercisable
within 60 days of March 1, 2024. |
(10) |
Consists of 33,354 ordinary shares and 30,149 ordinary shares issuable upon vesting of RSUs that vest within 60 days of March
1, 2024. |
(11) |
Consists of 33,354 ordinary shares and 30,149 ordinary shares issuable upon vesting of RSUs that vest within 60 days of March
1, 2024. In addition, Perception Capital Partners, LLC directly holds 75,000 ordinary shares and 3,047,669 warrants to purchase ordinary
shares at a price of $11.50 per share. Mr. Sheridan is the Chief Executive Officer of Perception Capital Partners, LLC and may be deemed
to be the beneficial owner of the securities held by Perception Capital Partners, LLC. |
(12) |
Consists of 15,274 ordinary shares issuable upon vesting of RSUs that vest within 60 days of March 1, 2024. |
(13) |
Consists of 10,500 ordinary shares issuable upon vesting of RSUs that vest within 60 days of March 1, 2024. |
Item 8. |
Financial Information |
Item 9. |
The Offer and Listing |
Item 10. |
Additional Information |
• |
amendments to our articles of association; |
• |
appointment, termination or the terms of service of our auditors; |
• |
appointment of external directors (if applicable); |
• |
approval of certain related party transactions; |
• |
increases or reductions of our authorized share capital; |
• |
mergers; and |
• |
the exercise of our board of director’s powers by a general meeting, if our board of directors is unable to exercise its powers
and the exercise of any of its powers is required for our proper management. |
• |
Form of Indemnification Agreement (incorporated by reference to Exhibit 10.12 to the Company’s Registration Statement on Form
F-4 (File No. 333-252023) filed with the SEC on February 12, 2021). See Item 6. “Directors,
Senior Management and Employees” for more information about this agreement. |
• |
Compensation Policy for Directors and Officers (incorporated by reference to Exhibit 10.13 to the Company’s Registration Statement
on Form F-4 (File No. 333-252023) filed with the SEC on February 12, 2021). See Item 6. “Directors,
Senior Management and Employees” for more information about this agreement. |
• |
2016 Share Incentive Plan of Innoviz Technologies Ltd. (incorporated by reference to Exhibit 10.10 to the Company’s Registration
Statement on Form F-4 (File No. 333-252023) filed with the SEC on February 12, 2021). See Item 6. “Directors,
Senior Management and Employees” for more information about this agreement. |
• |
2021 Share Incentive Plan of Innoviz Technologies Ltd. (incorporated by reference to Exhibit 4.4 to the Company’s Annual Report
on Form 20-F filed with the SEC on March 30, 2022). See Item 6. “Directors,
Senior Management and Employees” for more information about this agreement. |
• |
Warrant Agreement, dated as of April 30, 2020, between Continental Stock Transfer & Trust Company and Collective Growth Corporation
(incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form F-4 (File No. 333-252023) filed with
the SEC on January 11, 2021). See Exhibit 2.1 for more information about this agreement. |
• |
Assignment, Assumption and Amendment Agreement, by and among Innoviz Technologies Ltd., Collective Growth Corporation, American Stock
Transfer & Trust Company and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.11 to the Company’s
Annual Report on Form 20-F filed with the SEC on April 21, 2021). See Exhibit 2.1 for more information about this agreement. |
• |
Registration Rights Agreement, dated as of December 10, 2020, by and among Innoviz, certain equityholders of Innoviz, certain equityholders
of Collective Growth, Perception and Antara Capital (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement
on Form F-4 (File No. 333-252023) filed with the SEC on January 11, 2021). See Item 7.B. “Major
Shareholders and Related Party Transactions—Related Party Transactions” for more information about this agreement.
|
• |
Put Option Agreement, dated as of December 10, 2020, by and between Innoviz and Antara Capital (incorporated by reference to Exhibit
10.7 to the Company’s Registration Statement on Form F-4 (File No. 333-252023) filed with the SEC on January 11, 2021). See
Item 7.B. “Major Shareholders and Related Party Transactions—Related Party Transactions”
for more information about this agreement. |
• |
Magna Joint Development and Master Supply Agreement |
• |
BMW SOW |
• |
Magna Manufacturing MOU |
• |
Lease Agreement |
• |
Electronic Nomination Agreement with Cariad SE (a Volkswagen group company) |
• |
Agreement with Magna regarding Manufacturing of InnovizOne for the BMW Program
|
• |
Amortization of the cost of purchased patents, rights to use a patent, and know-how, which are used for the development
or advancement of the Industrial Enterprise, over an eight-year period, commencing on the year in which the Industrial Company began to
use them; |
• |
Under limited conditions, an election to file consolidated tax returns with controlled Israeli Industrial Companies; and |
• |
Expenses related to a public offering are deductible in equal amounts over three years commencing on the year of the offering.
|
• |
The expenditures are approved by the relevant Israeli government ministry, determined by the field of research; |
• |
The research and development must be for the promotion of the company; and |
• |
The research and development is carried out by or on behalf of the company seeking such tax deduction. |
• |
banks, financial institutions or insurance companies; |
• |
real estate investment trusts or regulated investment companies; |
• |
dealers or brokers; |
• |
traders that elect to mark to market; |
• |
tax exempt entities or organizations; |
• |
“individual retirement accounts” and other tax deferred accounts; |
• |
certain former citizens or long term residents of the United States; |
• |
persons that are resident or ordinarily resident in or have a permanent establishment in a jurisdiction outside the United States;
|
• |
persons that acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation for
the performance of services; |
• |
persons holding our ordinary shares or warrants as part of a “hedging,” “integrated” or “conversion”
transaction or as a position in a “straddle” for U.S. federal income tax purposes; |
• |
partnerships or other pass through entities and persons holding ordinary shares or warrants through partnerships or other pass through
entities; or |
• |
holders that own directly, indirectly or through attribution 10% or more of the total voting power or value of all of our outstanding
shares. |
• |
an individual who is a citizen or resident of the United States; |
• |
a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the
laws of the United States or any state thereof, including the District of Columbia; |
• |
an estate the income of which is subject to U.S. federal income taxation regardless of its source; or |
• |
a trust if such trust has validly elected to be treated as a United States person for U.S. federal income tax purposes or if (1) a
court within the United States is able to exercise primary supervision over its administration and (2) one or more United States
persons have the authority to control all of the substantial decisions of such trust. |
• |
any gain recognized by the U.S. Holder on the sale or other disposition of its ordinary shares or warrants; and |
• |
any “excess distribution” made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable
year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of the
ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter, such U.S. Holder’s holding period for
the ordinary shares). |
• |
the U.S. Holder’s gain or excess distribution will be allocated ratably over the U.S. Holder’s holding period for the
ordinary shares and warrants; |
• |
the amount allocated to the U.S. Holder’s taxable year in which the U.S. Holder recognized the gain or received the excess
distribution, or to the period in the U.S. Holder’s holding period before the first day of our first taxable year in which we are
a PFIC, will be taxed as ordinary income; |
• |
the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed
at the highest tax rate in effect for that year and applicable to the U.S. Holder; and |
• |
the interest charge generally applicable to underpayments of tax will be imposed in respect of the tax attributable to each such
other taxable year of the U.S. Holder. |
Item 11. |
Quantitative and Qualitative Disclosures About Market Risk
|
Item 12. |
Description of Securities Other than Equity Securities |
Item 13. |
Defaults, Dividend Arrearages and Delinquencies |
Item 14. |
Material Modifications to the Rights of Security Holders and Use
of Proceeds |
Item 15. |
Controls and Procedures |
Item 16A.
|
Audit Committee Financial Expert |
Item
16B. |
Code of Ethics |
Item
16C. |
Principal Accounting Fees and Services |
2023 |
2022 |
|||||||
(in thousands) |
||||||||
Audit Fees |
$ |
508 |
$ |
909 |
||||
Audit Related Fees
|
— |
— |
||||||
Tax Fees |
53 |
25 |
||||||
All Other Fees |
— |
— |
||||||
Total |
$ |
561 |
$ |
934 |
Item
16D. |
Exemptions from the Listing Standards for Audit Committees |
Item
16E. |
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
|
Item
16F. |
Change in Registrant’s Certifying Accountant |
Item
16G. |
Corporate Governance |
Item
16H. |
Mine Safety Disclosure |
Item
16I. |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
|
Item 16J.
|
Insider Trading Policies |
Item 16K.
|
Cybersecurity |
Item
17. |
Financial Statements |
Item
18. |
Financial Statements |
Item
19. |
Exhibits |
|
|
Incorporation by Reference | ||||
Exhibit No. |
Description |
Form |
File No. |
Exhibit No. |
Filing Date |
Filed / Furnished |
F-3 |
333‑265170 |
3.1 |
May 24, 2022 |
| ||
20-F |
001-40310 |
2.1 |
April 21, 2021 |
| ||
F-4 |
333-252023 |
10.12 |
February 12, 2021 |
| ||
F-4 |
333-252023 |
10.13 |
February 12, 2021 |
| ||
F-4 |
333-252023 |
10.10 |
January 11, 2021 |
| ||
20-F |
001-40310 |
4.4 |
March 30, 2022 |
| ||
F-4 |
333-252023 |
10.15 |
January 11, 2021 |
| ||
F-4 |
333-252023 |
10.16 |
January 11, 2021 |
| ||
F-4 |
333-252023 |
10.17 |
January 11, 2021 |
| ||
F-4 |
333-252023 |
10.18 |
January 11, 2021 |
| ||
F-4 |
333-252023 |
10.19 |
January 11, 2021 |
| ||
F-4 |
333-252023 |
4.4 |
January 11, 2021 |
|
20-F |
001-40310 |
4.11 |
April 21, 2021 |
| ||
F-4 |
333-252023 |
4.8 |
January 11, 2021 |
| ||
F-4 |
333-252023 |
10.7 |
January 11, 2021 |
| ||
20-F |
001-40310 |
4.14 |
March 30, 2022 |
| ||
20-F |
001-40310 |
4.15 |
March 9, 2023 |
|||
* | ||||||
|
|
|
|
* | ||
|
|
|
|
* | ||
|
|
|
|
* | ||
|
|
|
|
** | ||
|
|
|
|
** | ||
|
|
|
|
* | ||
* | ||||||
6-K |
001-40310 |
99.3 |
November 7, 2023 |
|||
* | ||||||
101.INS |
XBRL Instance Document. |
|
|
|
|
* |
101.SCH |
XBRL Taxonomy Extension Schema Document. |
|
|
|
|
* |
101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document. |
|
|
|
|
* |
101.DEF |
XBRL Taxonomy Definition Linkbase Document. |
|
|
|
|
* |
101.LAB |
XBRL Taxonomy Extension Label Linkbase Document. |
|
|
|
|
* |
101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
|
* |
* |
Filed herewith. |
** |
Furnished herewith. |
† |
Indicates management contract or compensatory plan or arrangement. |
†† |
Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit. |
|
INNOVIZ TECHNOLOGIES LTD. | |
|
| |
Date: March 12, 2024 |
By: |
/s/ Eldar Cegla |
|
|
Name: Eldar Cegla |
|
|
Title: Chief Financial Officer |
Page
|
|
Report of Independent Registered Public Accounting Firm (PCAOB ID
|
F-2
|
Report of Independent Registered Public Accounting Firm (PCAOB ID
|
F-3
|
F-4 - F-5
|
|
F-6
|
|
F-7
|
|
F-8 - F-9
|
|
F-10 - F-38
|
|
/s/
|
March 12, 2024
|
Certified Public Accountants (Isr.)
|
A member firm of PricewaterhouseCoopers International Limited
|
P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il
|
Kost Forer Gabbay & Kasierer
144 Menachem Begin Road,
Tel-Aviv 6492102, Israel
|
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com
|
/s/
|
A Member of EY Global
|
We have served as the Company’s auditor from 2016 to 2023.
|
|
March 9, 2023
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Short-term restricted cash
|
|
|
||||||
Bank deposits
|
|
|
||||||
Marketable securities
|
|
|
||||||
Trade receivables, net
|
|
|
||||||
Inventory
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
LONG-TERM ASSETS:
|
||||||||
Marketable securities
|
|
|
||||||
Restricted deposits
|
|
|
||||||
Property and equipment, net
|
|
|
||||||
Operating lease right-of-use assets, net
|
|
|
||||||
Other long-term assets
|
|
|
||||||
Total long-term assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
|
$
|
|
||||
Deferred revenues
|
|
|
||||||
Employees and payroll accruals
|
|
|
||||||
Accrued expenses and other current liabilities
|
|
|
||||||
Operating lease liabilities
|
|
|
||||||
Total current liabilities
|
|
|
||||||
LONG-TERM LIABILITIES:
|
||||||||
Deferred revenues
|
|
|
||||||
Operating lease liabilities
|
|
|
||||||
Warrants liability
|
|
|
||||||
Total long-term liabilities
|
|
|
||||||
SHAREHOLDERS’ EQUITY:
|
||||||||
Ordinary Shares of no-par value: Authorized:
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Total shareholders’ equity
|
|
|
||||||
Total liabilities and shareholders’ equity
|
$
|
|
$
|
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Revenues
|
$
|
|
$
|
|
$
|
|
||||||
Cost of revenues
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Gross loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Operating expenses:
|
||||||||||||
Research and development
|
|
|
|
|||||||||
Sales and marketing
|
|
|
|
|||||||||
General and administrative
|
|
|
|
|||||||||
Total operating expenses
|
|
|
|
|||||||||
Operating loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Financial income, net
|
|
|
|
|||||||||
Loss before taxes on income
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Taxes on income
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Basic and diluted net loss per ordinary share
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share
|
|
|
|
Convertible Preferred Shares
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Convertible Preferred Shares A
|
Convertible Preferred Shares B
|
Convertible Preferred
Shares B-1
|
Convertible Preferred Shares C
|
Convertible Preferred Shares C-1
|
Total
Amount
|
Ordinary Shares
|
Additional
Paid-in Capital
|
Accumulated
Deficit
|
Total
Shareholders’ Equity
(Deficit)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Number
|
Amount
|
Number
|
Amount
|
Number
|
Amount
|
Number
|
Amount
|
Number
|
Amount
|
Number
|
Amount
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2021
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||||||||||||||||||||||||
Issuance of Convertible Preferred Shares C-1
|
-
|
|
|
|
|
|
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of convertible preferred shares (see Note 1c)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
Issuance of ordinary shares in connection with PIPE offering, net of issuance costs (see Note 1c)
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Transactions, net of issuance cost (see Note 1c)
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification of warrants liability to equity
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of shares options
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of RSUs
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2021
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||||||||||||||||||||||||||||||
Reclassification of warrants liability to equity
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of shares options
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of public warrants
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of RSUs
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||||||||||||||||||||||||||||||
Issuance of ordinary shares, net of issuance costs
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification of warrants liability to equity
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of shares options
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of RSUs
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2023
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Cash Flows from Operating Activities:
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Adjustments required to reconcile net loss to net cash used in Operating Activities:
|
||||||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Remeasurement of warrants liability
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Issuance cost allocated to warrants liability
|
|
|
|
|||||||||
Change in accrued interest on bank deposits
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in marketable securities
|
(
|
)
|
|
|
||||||||
Share-based compensation
|
|
|
|
|||||||||
Realization of investment in non-marketable equity securities
|
|
|
(
|
)
|
||||||||
Capital gain, net
|
|
(
|
)
|
|
||||||||
Foreign exchange loss (gain), net
|
(
|
)
|
|
(
|
)
|
|||||||
Change in prepaid expenses and other assets
|
(
|
)
|
(
|
)
|
|
|||||||
Change in trade receivables, net
|
(
|
)
|
(
|
)
|
|
|||||||
Change in inventory
|
|
|
(
|
)
|
||||||||
Changes in operating lease assets and liabilities, net
|
|
|
|
|||||||||
Change in trade payables
|
|
|
(
|
)
|
||||||||
Change in accrued expenses and other liabilities
|
|
|
|
|||||||||
Change in employees and payroll accruals
|
|
(
|
)
|
|
||||||||
Change in deferred revenues
|
|
|
(
|
)
|
||||||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Cash flows from investing activities:
|
||||||||||||
Purchase of property and equipment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from sales of property and equipment
|
|
|
|
|||||||||
Investment in bank deposits
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Withdrawal of bank deposits
|
|
|
|
|||||||||
Investment in restricted deposits
|
(
|
)
|
(
|
)
|
|
|||||||
Withdrawal of restricted deposits
|
|
|
|
|||||||||
Investment in marketable securities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from sales and maturities of marketable securities
|
|
|
|
|||||||||
Proceeds from sale of non-marketable securities
|
|
|
|
|||||||||
Net cash provided by (used in) investing activities
|
$
|
|
$
|
|
$
|
(
|
)
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Cash flows from financing activities:
|
||||||||||||
Cash received from Transactions, net of issuance cost
|
|
|
|
|||||||||
Issuance of ordinary shares, net of issuance cost
|
|
|
|
|||||||||
Proceeds from exercise of options
|
|
|
|
|||||||||
Repayment of loans
|
|
|
(
|
)
|
||||||||
Net cash provided by financing activities
|
|
|
|
|||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
|
(
|
)
|
|
||||||||
Increase (decrease) in cash, cash equivalents and restricted cash
|
(
|
)
|
|
(
|
)
|
|||||||
Cash, cash equivalents and restricted cash at the beginning of the year
|
|
|
|
|||||||||
Cash, cash equivalents and restricted cash at the end of the year
|
$
|
|
$
|
|
$
|
|
||||||
Supplementary disclosure of cash flows activities:
|
||||||||||||
(1) Cash paid during the year for:
|
||||||||||||
Interest
|
$
|
|
$
|
|
$
|
|
||||||
Income taxes
|
$
|
|
$
|
|
$
|
|
||||||
(2) Non-cash transactions:
|
||||||||||||
Conversion of preferred shares to ordinary shares
|
$
|
|
$
|
|
$
|
|
||||||
Purchase of property and equipment
|
$
|
|
$
|
|
$
|
|
||||||
Reclassification of warrants liability to equity
|
$
|
|
$
|
|
$
|
|
||||||
Issuance cost paid in equity
|
$
|
|
$
|
|
$
|
|
||||||
Right-of-use assets recognized with corresponding lease liabilities
|
$
|
|
$
|
|
$
|
|
||||||
(3) Cash, cash equivalents and restricted cash at the end of the year:
|
||||||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
$
|
|
||||||
Short-term restricted cash
|
|
|
|
|||||||||
$
|
|
$
|
|
$
|
|
NOTE 1: - | GENERAL |
a. |
Innoviz Technologies Ltd. and its subsidiaries (the “Company” or “Innoviz”) is a Tier-1 direct supplier of high-performance, automotive grade LiDAR sensors and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The Company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles and trucks. The Company operates as a single operating segment.
|
b. |
The Company was incorporated on January 18, 2016, under the laws of the state of Israel.
|
c. |
On December 10, 2020, the Company entered into definitive agreements in connection with a merger (the “Transactions”) with Collective Growth Corporation (“Collective Growth”), a special purpose acquisition company, that resulted in Collective Growth becoming a wholly owned subsidiary of the Company upon the consummation of the Transactions on April 5, 2021 (the “Closing Date”).
|
F - 10
NOTE 1: - | GENERAL (Cont.) |
d. |
As of December 31, 2023, the Company’s principal source of liquidity includes its cash and cash equivalents in the amount of $
|
e. |
In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The intensity and duration of the war is difficult to predict, as such are the war’s economic implications on the Company’s operational and financial performance. The Company considered the impact of the war and determined that there were no material adverse impacts on the consolidated financial statements, including related significant estimates made by management, for the period ended December 31, 2023.
|
F - 11
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES |
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
a. |
Transactions: |
|
The Transactions were accounted for as a recapitalization as pre-combination Innoviz was determined to be the accounting acquirer under Financial Accounting Standards Board (FASB)’s Accounting Standards Codification Topic 805, Business Combinations (ASC 805). In connection with the recapitalization, outstanding share capital of the pre-combination Innoviz was converted into Company Ordinary Shares, representing a recapitalization, and the net assets of the Company remained at historical cost, with no goodwill or intangible assets recorded.
The pre-combination Innoviz was deemed to be the predecessor of the Company, and the consolidated assets and liabilities and results of operations prior to the Closing Date are those of the pre-combination Innoviz. |
Ordinary Share Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company’s own share and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.
Warrants that meet all the criteria for equity classification are recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.
Upon the closing of the Transactions,
Each warrant entitles the holder to purchase one Company Ordinary Share at a price of $ |
||
F - 12
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
As the private warrants include provisions that provide for potential changes to the settlement amounts that are dependent on the characteristics of the holder of the warrant, under ASC 815-40, those warrants are not indexed to the Company’s ordinary shares in the manner contemplated by that Section, so long as they are held by the initial purchasers or their permitted transferees. Therefore, the private warrants were classified as a liability, initially and subsequently measured at fair value through earnings.
Conversely, since the public warrants are indexed to the Company’s own share, they qualify for equity classification under ASC Section 815-40. |
b. |
Use of estimates:
|
|
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
|
||
Significant items subject to such estimates and assumptions include inventory reserves and useful lives of property, plant, and equipment. The Company bases these estimates on historical and anticipated results, trends and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from those estimates. |
c. |
Financial statements in U.S. dollars:
|
|
A substantial portion of the Company’s financing activities, including equity transactions and cash investments, are incurred in U.S. dollars. The Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S. dollar.
|
||
A subsidiary’s functional currency is the currency of the primary economic environment in which the subsidiary operates; normally, that is the currency of the environment in which a subsidiary primarily generates and expends cash. In making the determination of the appropriate functional currency for a subsidiary, the Company considers cash flow indicators, local market indicators, financing indicators and the subsidiary’s relationship with both the parent company and other subsidiaries. For subsidiaries that are primarily a direct and integral component or extension of the parent entity’s operations, the U.S. dollar is the functional currency.
|
||
F - 13
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
The Company has determined the functional currency of its foreign subsidiaries is the U.S. Dollar. The foreign operations are considered a direct and integral part or extension of the Company’s operations. The day-to-day operations of the foreign subsidiary are dependent on the economic environment of the U.S. Dollar.
Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with Statement of the Accounting Standard Codification (“ASC”) No. 830 “Foreign Currency Matters” (“ASC No. 830”). All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the statements of operations as financial income or expenses as appropriate.
|
d. |
Principles of consolidation:
|
|
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
|
e. |
Cash and cash equivalents, restricted cash and restricted deposits:
|
|
The Company considers all highly liquid short-term deposits with original maturities of three months or less from the investment date to be cash equivalents. Cash equivalents consist primarily of amounts invested in short term deposits. Restricted cash and restricted deposits consist deposits that serve as collateral mainly for lease agreements at the Company’s financial institutions.
|
f. |
Inventory:
|
|
Inventory is stated at the lower of cost or estimated net realizable value.
Cost of inventory is determined as follows:
Raw materials and work in process - based on weighted average cost.
Finished goods - based mainly on weighted average standard cost method.
The Company charges cost of revenues for write-downs of inventory which are obsolete or in excess of anticipated demand based on a consideration of marketability and product life cycle stage, product development plans, component cost trends, manufacturing yields, demand forecasts, historical revenue and assumptions about future demand and market conditions.
Losses expected to arise from firm non-cancelable commitments for future purchases of inventory are charged to cost of revenues unless the losses are recoverable through firm sales contracts or other means. |
F - 14
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
g. |
Property and equipment, net:
|
|
Property and equipment are stated at cost, net of accumulated depreciation and impairment. The estimated useful lives of property and equipment are determined when those assets are initially recognized and are routinely reviewed for the remaining estimated useful lives. When useful life is reassessed for an asset, the remaining carrying amount of the asset is accounted for prospectively and depreciated over the revised estimated useful life. Depreciation is calculated on a straight-line basis over the estimated useful lives of the related assets, at the following annual rates:
|
%
|
|
Computers and software
|
|
Office furniture and equipment
|
|
Machinery and lab equipment
|
|
Leasehold improvements
|
|
h. |
Impairment of long-lived assets:
|
|
Long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” (“ASC 360”), whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment exists when the carrying value of the asset exceeds the aggregate undiscounted cash flows expected to be generated by the asset. The impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During the years ended December 31, 2023, 2022 and 2021, the Company recorded impairment losses in the amount of $
|
i. |
Revenue recognition:
|
|
According to Accounting Standards Codification 606, Revenue from Contracts with Customers, and all the related amendments (“ASC 606”), a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.
The Company derives its revenues mainly from sales of LiDAR sensors, critical components and application engineering services for its customers. As such, the Company contracts with its customers, may contain the following main performance obligations: (i) sales of LiDAR sensors; (ii) sales of critical components; (iii) application engineering services. The Company evaluates each performance obligation to determine if it is satisfied at a point in time or over time.
|
F - 15
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
Revenue from LiDAR sensors and critical components is recognized at a point in time when the control of the goods is transferred to the customer, generally upon delivery.
Application engineering services to certain customers may require substantive customer acceptance due to performance acceptance criteria that is considered more than a formality. For these services, revenue is recognized at a point in time upon customer acceptance. During the year ended December 31, 2023 the Company recognized revenue at a point in time of $
The Company capitalizes costs of fulfilling application engineering services contracts, to the extent recoverable, that relate directly to contracts for which revenue recognition has yet to commence. These assets are amortized to cost of revenues consistently with the pattern of the revenue recognition of application engineering services.
The Company applies the practical expedient and does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.
For each contract which includes prepayment terms, the Company evaluates whether the contract includes a significant financing component. The Company’s contracts with customer prepayment terms do not include a significant financing component because the primary purpose is not to receive financing from the customers.
The Company’s general terms and conditions for its contracts do not contain a right of return that allows the customer to return products and receive a credit.
Deferred Revenues
Deferred revenues in the Company’s consolidated balance sheets, which represent contract liabilities, include mainly billings in excess of revenues recognized related to product sales and obligations under application engineering service agreements with OEMs and are recognized as revenues when the Company performs its obligations under the contract.
As of December 31, 2023, the Company received upfront payments in total of $
During the year ended December 31, 2023, the Company recognized $
During the year ended December 31, 2022, the Company recognized $
F - 16
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
j. |
Cost of revenues:
|
|
Cost of revenues include the manufacturing cost of LiDAR sensors, which primarily consists of components costs, sub-assembly costs and personnel-related costs, and amounts paid to third-party contract manufacturers and vendors. Cost of revenues also includes depreciation, costs of providing application engineering services (mainly personnel related costs), an allocated portion of overhead, warranty costs, excess and obsolete inventory and shipping costs.
|
k. |
Warranty provision:
|
|
The Company provides standard product warranties, for its pre-SOP products, for period of up to twelve months, at no extra charge, that covers the compliance of the products with agreed-upon specifications. Standard warranties are considered to be assurance type warranties and are not accounted for as separate performance obligations. A provision is recorded for estimated warranty costs based on the Company’s experience.
|
||
Changes in the warranty provision, presented in accrued expenses and other current liabilities, was as follow:
|
Year ended December 31,
|
||||||||
2023
|
2022
|
|||||||
Balance at the beginning of the year
|
$
|
|
$
|
|
||||
Warranty provision
|
|
|
||||||
Warranty claims settled
|
(
|
)
|
(
|
)
|
||||
Balance at the end of the year
|
$
|
|
$
|
|
l. |
Research and development expenses:
|
|
Research and development costs include mainly personnel-related expenses associated with the Company’s engineering personnel responsible for the design, development and testing of its products. Such costs related to software development are included in research and development expense until the technological feasibility is reached, which for the Company’s software products, is generally shortly before the products are released to production. Research and development costs are charged to the consolidated statements of operations as incurred.
|
F - 17
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
m. |
Patent costs:
|
|
Legal and related patent costs are charged to general and administrative expenses in the consolidated statements of operations as incurred, since their realization is uncertain. |
n. |
Leases
|
|
The Company applies ASU No. 2016-02, “Leases” Topic 842 (“ASC 842”) for its leases. The Company elected to not recognize a lease liability and a right-of-use (“ROU”) asset for leases with a term of twelve months or less. Lease payments on short-term leases are recognized as an expense on a straight-line basis over the lease term, not included in lease liabilities. Lastly, the Company also elected the practical expedient to not separate lease and non-lease components for its leases. The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct how and for what purpose the identified asset is used throughout the period of use. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease.
Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all of the Company’s lease contracts do not meet any of the criteria above, the Company concluded that all of its lease contracts should be classified as operation leases.
ROU assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise an extension option or not exercise a termination option.
For further information on the Company’s leasing activities see Note 6. |
F - 18
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
o. |
Share-based compensation:
|
|
The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation—Stock Compensation” (“ASC No. 718”). ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award is recognized as an expense over the requisite service period. |
||
The Company selected the Black-Scholes option pricing model as the most appropriate model for determining the fair value for its share options awards, whereas the fair value of restricted share units is based on the closing market value of the underlying shares at the date of grant. The option pricing model requires several assumptions, of which the most significant are the expected share price volatility and the expected option term. The Company recognizes forfeitures of equity-based awards as they occur. For graded vesting awards subject to a service condition only, the Company recognizes compensation expenses based on the straight-line method over the requisite service period.
A Monte-Carlo simulation model was used to determine the grant date fair value of the Company’s Management earn-out shares by simulating the future share price daily up to the expiration date of the award. For each simulation path we determined the value of the award. The grant date fair value of this award is the average of the values determined by each simulation. The simulation was also used to derive the requisite service period (see Note 12d).
|
p. |
Accrued post-employment benefit:
|
|
Severance pay
|
||
The Israeli Severance Pay Law, 1963 (“Severance Pay Law”), specifies that employees are entitled to severance payment, following the termination of their employment. Under the Severance Pay Law, the severance payment is calculated as one-month salary for each year of employment, or a portion thereof.
|
The Company’s liability for all of its Israeli employees is covered by the provisions of Section 14 of the Severance Pay Law (“Section 14”). Under Section 14 employees are entitled to monthly deposits, at a rate of
Severance pay expenses under Section 14 for the years ended December 31, 2023, 2022 and 2021, amounted to $ |
F - 19
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
q. |
Income taxes:
|
|
The Company accounts for income taxes in accordance with ASC No. 740, “Income Taxes” (“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value, if it is more likely than not that a portion or all of the deferred tax assets will not be realized. |
||
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. Accounting guidance addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements, under which a Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. |
r. |
Concentration of credit risk:
|
|
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, trade receivables, marketable securities, bank deposits and restricted deposits.
The majority of the Company’s cash and cash equivalents and short-term bank deposits are invested with major banks in Israel. The Company believes that the financial institutions that hold the Company’s cash deposits are financially sound and, accordingly, bear minimal risk.
|
Trade receivables of the Company are mainly derived from customers located globally. The Company mitigates its credit risks by performing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances. The Company generally does not require collateral.
The Company invests in marketable securities with an average credit rating of “A” and a maturity of up to three years. The Company’s investment policy is not to invest more than |
s. |
Trade receivables, net:
|
|
Trade receivables are recorded at the invoiced amount and do not bear interest. Trade receivables are periodically assessed for allowance for doubtful accounts, which is the Company’s best estimate of the amount of credit losses inherent in its existing accounts receivable. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and customers’ financial condition, the amount of receivables in dispute, the current receivables aging, in addition to current and expected payment patterns. The allowance of doubtful accounts was not material for the periods presented.
|
F - 20
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
t. | Investment in marketable securities: |
u. |
Fair value of financial instruments:
|
|
The Company applies ASC No. 820, “Fair Value Measurements and Disclosures” (“ASC No. 820”), with respect to fair value measurements of all financial assets and liabilities which are required to be measured at fair value. |
||
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:
|
Level 1 - |
Unadjusted quoted prices in active markets that are accessible on the measurement date for identical, unrestricted assets or liabilities. |
||
Level 2 - |
Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.
|
Level 3 - |
Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
|
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
|
The carrying values of cash and cash equivalents, short-term and restricted deposits, trade receivables, other current assets, trade payables, employees and payroll accruals and accrued expenses and other current liabilities approximate fair values due to the short-term maturities of these instruments.
|
F - 21
NOTE 2:- |
SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
v. |
Loss per share:
|
|
The Company computes basic loss per share in accordance with ASC Topic 260, “Earnings per Share”, by dividing the net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is computed by considering the potential dilution that could occur upon the exercise of awards granted under share-based compensation plans and equity-classified instruments using the treasury stock method. Impact of liability-classified instruments on diluted loss per share is considered using the if-converted method. Diluted loss per share excludes all dilutive potential ordinary shares if their effect is anti-dilutive.
|
||
Prior to the Transactions, the Company computed net loss per share using the two-class method required for participating securities. The two-class method requires income available to common shareholders for the period to be allocated between common shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its preferred shares to be participating securities as the holders of the preferred shares were entitled to dividends that would have been distributed to the holders of common shares, on a pro-rata basis assuming conversion of all preferred shares into common shares. These participating securities did not contractually require the holders of such shares to participate in the Company’s losses. As such, net loss for the periods presented was not allocated to the Company’s participating securities.
|
w. |
Other comprehensive loss:
|
|
The Company has no components of comprehensive loss other than net loss. Thus, comprehensive loss is the same as net loss for the periods presented.
|
x. |
Recently adopted accounting pronouncement:
|
On January 1, 2023, the Company adopted ASU No. 2016-13 (Topic 326), Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which has replaced the previous incurred loss impairment methodology. Under the new guidance an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements. |
y. |
Recently issued accounting pronouncements not yet adopted:
|
1. |
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the effect that ASU 2023-07 will have on its consolidated financial statements and related disclosures.
|
2. |
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option. The Company is in the process of assessing the impacts and method of adoption. The Company is currently evaluating the effect that ASU 2023-09 will have on its consolidated financial statements and related disclosures.
|
a. |
Inventory is comprised of the following:
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
Raw materials
|
$
|
|
$
|
|
||||
Work in process
|
|
|
||||||
Finished goods
|
|
|
||||||
|
||||||||
$
|
|
$
|
|
b. |
During the years ended December 31, 2023, 2022 and 2021, the Company recorded inventory write offs in the amount of $
|
F - 22
NOTE 4: - |
PREPAID EXPENSES AND OTHER CURRENT ASSETS
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
Government authorities
|
$
|
|
$
|
|
||||
Prepaid expenses
|
|
|
||||||
Deferred contract costs
|
|
|
||||||
Other receivables
|
|
|
||||||
|
||||||||
$
|
|
$
|
|
NOTE 5: - |
PROPERTY AND EQUIPMENT, NET
|
a. |
Property and equipment, net consist of the following:
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
Cost:
|
||||||||
Computers and software
|
|
|
||||||
Office furniture and equipment
|
|
|
||||||
Machinery and lab equipment
|
|
|
||||||
Leasehold improvements
|
|
|
||||||
|
|
|||||||
Accumulated depreciation
|
|
|
||||||
|
||||||||
$
|
|
$
|
|
b. |
Depreciation expenses for the years ended December 31, 2023, 2022 and 2021, amounted to $
|
NOTE 6: - |
LEASES
|
F - 23
NOTE 6: - | LEASES (Cont.) |
Below is a summary of the Company operating right-of-use assets, net and operating lease liabilities:
December 31,
|
||||||||
2023
|
2022
|
|||||||
Operating lease right-of-use assets, net
|
$
|
|
$
|
|
||||
|
||||||||
Operating lease liabilities, current
|
$
|
|
$
|
|
||||
Operating lease liabilities, non-current
|
|
|
||||||
|
||||||||
Total operating lease liabilities
|
$
|
|
$
|
|
||||
Weighted average remaining lease term (years)
|
|
|
||||||
Weighted average discount rate of operating leases
|
|
%
|
|
%
|
Year ended December 31,
|
||||||||
2023
|
2022
|
|||||||
Operating lease costs
|
$
|
|
$
|
|
||||
Variable lease payments
|
$
|
|
$
|
|
||||
Short term lease costs
|
$
|
|
$
|
|
||||
Cash paid for operating leases, net of operating cash flows from lease incentives received
|
$
|
|
$
|
(
|
)
|
Year ended December 31,
|
||||
2024
|
$
|
|
||
2025
|
|
|||
2026
|
|
|||
2027
|
|
|||
2028 and thereafter
|
|
|||
|
||||
Total undiscounted lease payments
|
$
|
|
||
|
||||
Less: interest
|
|
|||
|
||||
Present value of lease liabilities
|
$
|
|
F - 24
NOTE 7: - | FAIR VALUE MEASUREMENTS |
December 31, 2023
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
Assets:
|
||||||||||||||||
Marketable securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
||||||||||||||||
Total financial assets
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Liabilities:
|
||||||||||||||||
Warrants (1)
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Total financial liabilities
|
$
|
|
$
|
|
$
|
|
$
|
|
December 31, 2022
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
||||||||||||
Assets:
|
||||||||||||||||
Marketable securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
||||||||||||||||
Total financial assets
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Liabilities:
|
||||||||||||||||
Warrants (1)
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Total financial liabilities
|
$
|
|
$
|
|
$
|
|
$
|
|
F - 25
NOTE 7: - |
FAIR VALUE MEASUREMENTS (Cont.)
|
(1) |
As part of the Transactions (see Note 1c), the Company assumed a derivative warrants liability related to previously issued private placement warrants in connection with Collective Growth’s initial public offering. The Company utilizes a Black-Scholes option pricing model to estimate the fair value of the private placement warrants which is considered a Level 3 fair value measurement. The warrants are measured at each reporting period, with changes in fair value recognized in financing income, net. The change in the fair value of the derivative private warrants liability for the years ended December 31, 2023, 2022 and 2021 is summarized as follows:
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Balance at the beginning of the period
|
$
|
|
$
|
|
$
|
|
||||||
Private warrants liability assumed in Transactions
|
|
|
|
|||||||||
Change in fair value of warrants liability
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Reclassification of warrants liability to equity
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Balance at the end of the year
|
$
|
|
$
|
|
$
|
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
Fair value determined per warrant
|
$
|
|
$
|
|
||||
Expected volatility
|
|
%
|
|
%
|
||||
Expected annual dividend yield
|
|
%
|
|
%
|
||||
Expected term (years)
|
|
|
||||||
Risk-free rate
|
|
%
|
|
%
|
NOTE 8: - |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
Warranty provision
|
$
|
|
$
|
|
||||
Accrued expenses
|
|
|
||||||
Fixed assets creditors
|
|
|
||||||
Others
|
|
|
||||||
|
||||||||
$
|
|
$
|
|
F - 26
NOTE 9: - |
COMMITMENTS AND CONTINGENCIES
|
NOTE 10: - |
CONVERTIBLE PREFERRED SHARES
|
a. |
Upon closing of the Transactions, all issued and outstanding Preferred Shares were automatically converted into Ordinary Shares of no-par value. As such, the Company reclassified the preferred shares carrying amount into permanent equity (for further information see Note 1c).
|
b. |
Preferred shares A, B, B-1, C, and C-1 (collectively “Preferred Shares”) conferred upon their holders the same rights conferred by the Company’s legacy Ordinary Shares (for further information see Note 11a) in addition to the following rights:
|
F - 27
NOTE 10: - |
CONVERTIBLE PREFERRED SHARES (Cont.)
|
I. |
First, the holders of the Preferred C and C-1 Shares (collectively “Preferred C Shares”) were entitled to receive, prior to any distribution to any other shareholder, on a proportional basis an amount equal to the original issue price for such series of Preferred Share, plus interest at a rate of
|
II. |
Second, the holders of the Preferred B and B-1 Shares (collectively “Preferred B Shares”) were entitled to receive, in preference to each inferior class, on a proportional basis an amount calculated in the same manner as described above with respect to the Preferred C Shares.
|
III. |
Third, the holders of the Preferred A Shares were entitled to receive, in preference to each inferior class, an amount calculated in the same manner as described above with respect to the Preferred C Shares.
|
IV. |
Following the full payment of the entire preferred preference to the holders of Preferred Shares, the holders of the Ordinary Shares were entitled to receive the remaining distribution proceeds (if any), pro rata based on the number of Ordinary Shares held by each such holder.
|
c. |
On October 1, 2020, the Company closed its initial Series C-1 Preferred Share financing round with new and existing investors, according to which the Company issued
|
1. |
In the event that: (i) definitive agreement in connection with transaction between the Company and a SPAC, had not been signed prior to December 31, 2020, or (ii) the closing of the Transactions contemplated under such aforementioned definitive agreements shall not have taken place prior to April 30, 2021, the Company were to issue additional Preferred C-1 Shares for no additional consideration, such that after the issuance of the additional Preferred C-1 Shares, the aggregate number of Preferred C-1 Shares held by such investors were equal to the aggregate investment made by the investor divided by price per share as defined in the transaction documents (for the Preferred C-1 Shares actually issued see Note 10e).
|
F - 28
NOTE 10: - |
CONVERTIBLE PREFERRED SHARES (Cont.)
|
2. |
In the event the closing of the Transactions contemplated under such aforementioned definitive agreements shall have taken place prior to April 30, 2021, with pre-money valuation of the Company lower than $
|
d. |
See Note 11b for reverse share split which occurred on February 17, 2021.
|
e. |
Immediately prior to the closing of the Transactions, and in accordance with the Preferred C-1 transaction documents, the Company issued to certain shareholders
|
f. |
During the year ended December 31, 2020, the Company capitalized $
|
g. |
Classification:
|
F - 29
NOTE 11: - |
SHAREHOLDERS’ EQUITY
|
a. |
Composition of share capital:
|
December 31,
|
||||||||||||||||
2023
|
2022
|
|||||||||||||||
Authorized
|
Issued and outstanding
|
Authorized
|
Issued and outstanding
|
|||||||||||||
Number of Shares
|
Number of Shares
|
|||||||||||||||
Ordinary Shares of no-par value (1)
|
|
|
|
|
(1) |
Ordinary Shares confer upon the holders the right to vote in annual and special meetings of the Company, and to participate in the distribution of the surplus assets of the Company upon liquidation of the Company.
|
b. |
On February 17, 2021, the Company effected a 1-for-
|
c. |
On August 14, 2023 and on September 12, 2023, the Company issued a total of
|
NOTE 12: - |
SHARE-BASED COMPENSATION
|
a. |
Share incentive plans:
|
F - 30
NOTE 12: - |
SHARE-BASED COMPENSATION (Cont.)
|
b. |
Options granted:
|
Year ended December 31,
|
|||||||||||
2023
|
2022
|
2021
|
|||||||||
Expected term, in years
|
|
|
|
||||||||
Expected volatility
|
|
|
|
||||||||
Risk-Free interest rate
|
|
|
|
||||||||
Expected dividend yield
|
|
|
|
|
Number of options
|
Weighted-average exercise price
|
Weighted- average remaining contractual term
(in years)
|
Aggregate intrinsic value
|
|||||||||||||
Outstanding at January 1, 2023
|
|
$
|
|
|
$
|
|
||||||||||
Granted
|
|
$
|
|
|||||||||||||
Exercised
|
|
$
|
|
$
|
|
|||||||||||
Forfeited
|
|
$
|
|
|||||||||||||
Expired
|
|
$
|
|
|||||||||||||
Outstanding at December 31, 2023
|
|
$
|
|
|
$
|
|
||||||||||
Exercisable at December 31, 2023
|
|
$
|
|
|
$
|
|
F - 31
NOTE 12: - |
SHARE-BASED COMPENSATION (Cont.)
|
c. |
RSUs granted:
|
Number of
shares
|
Weighted average grant date fair value per share
|
|||||||
Unvested as of December 31, 2022
|
|
$
|
|
|||||
Granted
|
|
$
|
|
|||||
Vested
|
|
$
|
|
|||||
Forfeited
|
|
$
|
|
|||||
Unvested as of December 31, 2023
|
|
$
|
|
F - 32
NOTE 12: - |
SHARE-BASED COMPENSATION (Cont.)
|
d. |
Management earn-out shares:
|
May 12, 2021
|
||||
Share Price
|
$
|
|
||
Expected volatility
|
|
%
|
||
Risk-Free interest rate
|
|
%
|
||
Threshold
|
$
|
|
||
Term (years)
|
|
e. |
The total share-based compensation expense related to all of the Company’s equity-based awards, which include options and RSUs recognized in the Company’s consolidated statements of operations are as follow:
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Cost of revenues
|
$
|
|
$
|
|
$
|
|
||||||
Research and development
|
|
|
|
|||||||||
Sales and marketing
|
|
|
|
|||||||||
General and administrative
|
|
|
|
|||||||||
|
||||||||||||
$
|
|
$
|
|
$
|
|
f. |
For awards issued for non-employees’ services, see Note 1c.
|
F - 33
NOTE 13: - |
TAXES ON INCOME
|
a. |
Corporate tax rates in Israel:
|
b. |
Income taxes of non-Israeli subsidiaries:
|
c. |
Carryforward tax losses and credits:
|
d. |
Deferred income taxes:
|
December 31,
|
||||||||
2023
|
2022
|
|||||||
Deferred tax assets:
|
||||||||
Net operating loss carryforward
|
$
|
|
$
|
|
||||
Research and development costs carryforward
|
|
|
||||||
Capital loss carryforward
|
|
|
||||||
Inventory provision
|
|
|
||||||
Accrued expenses
|
|
|
||||||
Property and equipment
|
|
|
||||||
Lease liabilities
|
|
|
||||||
Other
|
|
|
||||||
Total deferred tax assets
|
|
|
||||||
Valuation allowance
|
(
|
)
|
(
|
)
|
||||
Deferred tax liabilities:
|
||||||||
Right-of-use assets
|
(
|
)
|
(
|
)
|
||||
Other
|
(
|
)
|
|
|||||
Total deferred tax liabilities
|
(
|
)
|
(
|
)
|
||||
Net deferred tax
|
$
|
|
$
|
|
F - 34
NOTE 13: - |
TAXES ON INCOME (Cont.)
|
e. |
Loss before taxes on income is comprised as follows:
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Domestic (Israel)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Foreign
|
|
|
(
|
)
|
||||||||
|
||||||||||||
Loss before taxes on income
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
f. |
Income taxes are comprised as follows:
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Current
|
$
|
|
$
|
|
$
|
|
||||||
Domestic (Israel)
|
|
|
|
|||||||||
Foreign
|
|
|
|
|||||||||
|
||||||||||||
Income taxes
|
$
|
|
$
|
|
$
|
|
g. |
The reconciliation of the tax benefit at the Israeli statutory tax rate to the Company’s income taxes is as follows:
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Israel tax provision at statutory rate
|
|
%
|
|
%
|
|
%
|
||||||
Non-deductible share-based compensation
|
(
|
)%
|
(
|
)%
|
(
|
)%
|
||||||
Effect of other permanent differences
|
(
|
)%
|
|
%
|
|
%
|
||||||
Change in valuation allowance
|
(
|
)%
|
(
|
)%
|
(
|
)%
|
||||||
Issuance costs
|
|
%
|
|
%
|
|
%
|
||||||
Provision to return
|
|
%
|
(
|
)%
|
(
|
)%
|
||||||
Capital losses
|
|
%
|
|
|
||||||||
Other adjustments
|
|
%
|
|
%
|
(
|
)%
|
||||||
|
||||||||||||
Effective tax rate
|
(
|
)%
|
(
|
)%
|
(
|
)%
|
F - 35
NOTE 13: - |
TAXES ON INCOME (Cont.)
|
h. |
Tax assessments:
|
i. |
Uncertain tax positions:
|
NOTE 14: - |
BASIC AND DILUTED NET LOSS PER SHARE
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Numerator:
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Preferred share accrued cumulative dividend rights
|
|
|
(
|
)
|
||||||||
Total loss attributable to ordinary shares
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Denominator:
|
||||||||||||
|
||||||||||||
|
|
|
a. |
|
b. |
|
c. |
|
F - 36
NOTE 15: - |
SALE OF NON-MARKETABLE SECURITIES
|
NOTE 16: - | GEOGRAPHIC AND CUSTOMER INFORMATION |
a. |
Geographic information:
|
Year ended December 31,
|
||||||||||||
2023
|
2022
|
2021
|
||||||||||
Europe, Middle East and Africa (*)
|
$
|
|
$
|
|
$
|
|
||||||
Asia Pacific
|
|
|
|
|||||||||
North America (**)
|
|
|
|
|||||||||
$
|
|
$
|
|
$
|
|
(*) |
Includes revenues from Germany in the amount of $
|
(**) |
Includes revenues from United States only.
|
b. |
The Company’s long-lived assets (property and equipment, net and operating lease right-of-use assets, net) are located as follows:
|
Year ended December 31,
|
||||||||
2023
|
2022
|
|||||||
Israel
|
$
|
|
$
|
|
||||
United States
|
|
|
||||||
Germany
|
|
|
||||||
Others
|
|
|
||||||
$
|
|
$
|
|
F - 37
NOTE 16: - | GEOGRAPHIC AND CUSTOMER INFORMATION (Cont.) |
c. |
Customers accounted for over 10% of revenues:
|
d. |
Concentration of credit risk from major customers customers:
|
F - 38